MediMabBio is advancing next-generation immunotherapies through its proprietary MediLink™ fusion-antibody platform, which combines antibodies with immune-modulating cytokines to deliver enhanced therapeutic efficacy and safety. The lead programme, MFA031, is a fusion protein which restores immune balance in indications such as autoimmune disease and transplant rejection.
The Series B round was led by existing investors, including KB Investment, Smilegate Investment, BNH Investment, Hyundai Investment Partners, IM Investment Partners, and Timefolio Asset Management, with participation from eight new institutional investors — Yuanta Investment, Seoul Investment Partners, Sneak Peek Investment, Union Investment Partners, Aon Investment, E&Venture Partners, Dongbang FTL, and HLB Bios Step.